Buy now for a tactical rebound setup: BILL is extremely oversold (RSI-6 ~12.7) and trading near key support (S1 38.80 / S2 35.76), which favors a snap-back move.
Sentiment skew is bullish (options put/call ratios are low; hedge funds are buying aggressively), which supports near-term upside despite the weak trend.
Near-term catalyst: Earnings on 2026-02-05 (after hours) can re-rate the stock quickly; with the stock already heavily sold-off, the risk/reward leans favorable for an impatient buyer.
Volatility: 30D IV 58.14 vs HV 48.17 → options pricing in elevated moves (event-sensitive).
IV percentile: 64.8 (moderately elevated) → sentiment expects a meaningful move around upcoming earnings.
Activity: Today’s volume 3088 (with elevated vs typical context in the dataset) → traders actively positioning.
Technical Summary
Sell
3
Buy
11
Positive Catalysts
can spark a sharp re-rate if results/guidance stabilize.
Neutral/Negative Catalysts
Price action / sentiment: Stock down -61.5% YoY and -26.7% in 30 days → damaged trend and fragile confidence.
Momentum still worsening: MACD bearish and expanding → downside pressure not definitively finished.
Profitability setback: Latest quarter shows net loss (see financials) → limits multiple expansion without a clearer profitability path.
Analyst target trimming: Multiple firms have reduced targets into earnings → indicates tempered expectations.
No supportive insider signal: Insiders are neutral (no meaningful recent bullish insider buying trend indicated).
Financial Performance
Latest quarter: 2026/Q1
Revenue: $395.741M, +10.40% YoY (growth still positive).
Net Income: -$2.962M, down -133.24% YoY (turned worse vs prior year).
EPS: -0.03, down -137.50% YoY.
Gross Margin: 78.5%, down -1.18% YoY (still very high, but slightly compressing).
Takeaway: Growth persists, but profitability and margin trend weakened—market will likely focus on forward guidance and margin/profit trajectory at the next print.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent rating/target trend: Targets have been trimmed by some bullish firms into earnings (e.g., Citi $71→$62, Truist $60→$58), while others remain constructive; overall tone is cautious-optimistic.
Latest notable takes:
Baird: Neutral, sees potential takeover value $55–$70, PT $56.
Citi (Bryan Keane): Buy, PT $62.
Truist: Buy, PT $58.
Keefe Bruyette: Market Perform, PT $60.
JPMorgan: Overweight, PT $60.
UBS: Buy, PT $60.
Wall Street pros (bull case): Strategic/takeout optionality mentioned; multiple Buy/Overweight ratings; targets mostly well above current price.
Wall Street cons (bear case): Several Market Perform/Neutral stances and repeated target reductions reflect concern about growth comps and the need for cleaner profitability signals.
Politicians/Congress: No recent congress trading data available (no identified political trading signal).
People Also Watch
Wall Street analysts forecast BILL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BILL is 60.8 USD with a low forecast of 43 USD and a high forecast of 84 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
Wall Street analysts forecast BILL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BILL is 60.8 USD with a low forecast of 43 USD and a high forecast of 84 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
7 Hold
0 Sell
Moderate Buy
Current: 35.680
Low
43
Averages
60.8
High
84
Current: 35.680
Low
43
Averages
60.8
High
84
Keefe Bruyette
Market Perform
downgrade
$60 -> $49
AI Analysis
2026-02-06
New
Reason
Keefe Bruyette
Price Target
$60 -> $49
AI Analysis
2026-02-06
New
downgrade
Market Perform
Reason
Keefe Bruyette lowered the firm's price target on Bill to $49 from $60 and keeps a Market Perform rating on the shares.
Jefferies
Buy
downgrade
$55 -> $50
2026-02-06
New
Reason
Jefferies
Price Target
$55 -> $50
2026-02-06
New
downgrade
Buy
Reason
Jefferies lowered the firm's price target on Bill to $50 from $55 and keeps a Buy rating on the shares. Fiscal Q2 results mostly beat expectations and "mark a much-needed step in the right direction," the analyst tells investors. The key to driving the stock materially higher will be sustaining this for multiple quarters, the analyst added.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BILL
